Nesina 6.25 mg/1

Nesina Tablet, film coated is a product of Takeda

Group: Approved DPP-IV Inhibitors / Incretins

Name: Nesina

Dosage: Tablet, film coated

Strength: 6.25 mg/1

Route: Oral

Pharmaceutical company : Takeda

You can also find other alternative products such as : Nesina (25 mg/1) from Takeda Nesina (6.25 mg) from Takeda Nesina (25 mg) from Takeda Nesina (25 mg) from Takeda Nesina (6.25 mg/1) from Takeda Nesina (6.25 mg) from Takeda

Indication: Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Category:

  • Agents causing angioedema
  • Alimentary Tract and Metabolism
  • Blood Glucose Lowering Agents
  • Cytochrome P-450 CYP2D6 Substrates
  • Cytochrome P-450 CYP3A Substrates
  • Cytochrome P-450 CYP3A4 Substrates
  • DPP-IV Inhibitors
  • Drugs Used in Diabetes
  • Enzyme Inhibitors
  • Hormones
  • Hormones, Hormone Substitutes, and Hormone Antagonists
  • Incretins
  • Oral Hypoglycemics
  • Pyrimidines
  • Pyrimidinones
  • Food Interactions; Not Available

    Alogliptin Definition:
    Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.

    More Nesina 6.25 mg/1

    Nesina

    Therapeutic indications Alogliptin is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes

    A very serious allergic reaction to this drug is rare..Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects..This is not a complete list of possible side effects..
    What should I know regarding pregnancy, nursing and administering Nesina to children or the elderly?**Interactions**Drug interactions may change how your medications work or increase your risk for serious side effects..**Precautions**Before taking alogliptin, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies.. Do not start, stop, or change the dosage of any medicines without your doctor's approval..


    NESINA Rx

    Therapeutic indications Diabetes


    Obtain LFTs before starting therapy; interrupt and evaluate if liver enzymes elevated or abnormal tests persist; do not restart if liver injury is confirmed and no other etiology can be found.. Interactions: May need lower dose of concomitant sulfonylurea or insulin to reduce risk of hypoglycemia.. Generic Availability: NO How Supplied: 6..


    NESINA Rx

    Therapeutic indications Diabetes


    Consider risks/benefits in patients with known risk factors for heart failure; monitor for signs/symptoms; evaluate and consider discontinuing if develops.. Generic Availability: NO How Supplied: 6..B)..


    Other drugs that have exactly the same effects, dosage, intended use, side effects, route of administration, risks, safety, and strength as Alogliptin

    Name Pharmaceutical
    Alogliptin 25 mg/1Perrigo New York Inc.
    Alogliptin 6.25 mg/1Perrigo New York Inc.
    Alogliptin 6.25 mg/1Perrigo New York Inc.

    Drug mixture that contained Alogliptin

    Name Pharmaceutical
    Incresync Tablet, film coatedTakeda Pharma A/S
    Alogliptin and Metformin Hydrochloride Tablet, film coatedPerrigo New York Inc.
    Incresync Tablet, film coatedTakeda Pharma A/S
    Oseni TabletTakeda
    Oseni Tablet, film coatedTakeda
    Kazano Tablet, film coatedTakeda
    Incresync Tablet, film coatedTakeda Pharma A/S
    Oseni TabletTakeda
    Kazano TabletTakeda
    Incresync Tablet, film coatedTakeda Pharma A/S

    Effects of Nesina 6.25 mg/1 by reaction with another drug or drugs

  • Methyl salicylate may increase the hypoglycemic activities of Alogliptin.
  • The therapeutic efficacy of Alogliptin can be increased when used in combination with Acetazolamide.
  • The therapeutic efficacy of Alogliptin can be decreased when used in combination with Pentamidine.
  • Tirofiban may decrease the excretion rate of Alogliptin which could result in a higher serum level.
  • Zaleplon may decrease the excretion rate of Alogliptin which could result in a higher serum level.
  • The serum concentration of Alogliptin can be increased when it is combined with Stiripentol.
  • Oxymetholone may increase the hypoglycemic activities of Alogliptin.
  • Zaleplon may decrease the excretion rate of Alogliptin which could result in a higher serum level.
  • The serum concentration of Alogliptin can be increased when it is combined with Simeprevir.
  • The serum concentration of Alogliptin can be decreased when it is combined with Pitolisant.
  • The metabolism of Alogliptin can be increased when combined with Temozolomide.
  • The metabolism of Alogliptin can be decreased when combined with Mibefradil.
  • The serum concentration of Alogliptin can be increased when it is combined with Cobicistat.
  • Milnacipran may increase the hypoglycemic activities of Alogliptin.
  • Nedocromil may decrease the excretion rate of Alogliptin which could result in a higher serum level.
  • The therapeutic efficacy of Alogliptin can be decreased when used in combination with Ethynodiol diacetate.
  • The therapeutic efficacy of Alogliptin can be increased when used in combination with Furosemide.
  • Testosterone propionate may increase the hypoglycemic activities of Alogliptin.
  • The risk or severity of adverse effects can be increased when Alogliptin is combined with Imidapril.
  • The therapeutic efficacy of Alogliptin can be increased when used in combination with Rosuvastatin.